Product nameAnti-PPAR gamma antibody
See all PPAR gamma primary antibodies
DescriptionRabbit polyclonal to PPAR gamma
SpecificityNo significant homology with PPAR alpha or NUC1.
Tested applicationsSuitable for: IHC, WB, ICC/IFmore details
Species reactivityReacts with: Mouse, Rat, Human, Pig
- 3T3-L1 differentiated cells and cell lysates
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.05% Sodium azide
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Fatty acids
Our Abpromise guarantee covers the use of ab209350 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC||Use at an assay dependent concentration.|
|WB||1/500 - 1/1000. Predicted molecular weight: 57 kDa.|
|EMSA||Use at an assay dependent concentration.|
FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
- Information by UniProt
- CIMT1 antibody
- GLM1 antibody
- NR1C3 antibody
Immunocytochemical analysis of PPAR gamma using ab209350 at the dilution 1/200. 3T3-L1 cells providing positive signal have been differentiated for 7 days.
PPAR gamma is shown in red, lipid droplets (that indicates the proper differentiation of the cells) are shown in green.
All lanes : Anti-PPAR gamma antibody (ab209350)
Lane 1 : NIH/3T3 cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : K562 cell lysate
Lane 4 : PC-12 cell lysate
Lane 5 : U-87 MG cell lysate
Predicted band size: 57 kDa
All lanes : Anti-PPAR gamma antibody (ab209350) at 1/500 dilution
Lane 1 : 3T3
Lane 2 : 3T3-L1 differentiated day 7
Lysates/proteins at 20 µg per lane.
Predicted band size: 57 kDa
Specific band detected in 3T3-L1 day 7 differentiated lysate with no reactivity in 3T3 lysate.
Immunocytochemical analysis of PPAR gamma using ab209350 at the dilution 1/200.The image at the top shows 3T3-L1 cells differntiated (for 7 days) where PPAR gamma is shown in green. The image below shows 3T3-L1 undifferentiated cells where no PPAR gamma is detected.
This product has been referenced in:
- Tao L et al. Recombinant human glucagon-like peptide-1 protects against chronic intermittent hypoxia by improving myocardial energy metabolism and mitochondrial biogenesis. Mol Cell Endocrinol 481:95-103 (2019). Read more (PubMed: 30503377) »
- Li Y et al. Rosiglitazone attenuates cell apoptosis through antioxidative and anti-apoptotic pathways in the hippocampi of spontaneously hypertensive rats. Int J Mol Med 43:693-700 (2019). Read more (PubMed: 30483729) »